BMO Capital Maintains Outperform on AstraZeneca, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained an Outperform rating on AstraZeneca (NASDAQ:AZN) and raised the price target from $80 to $82.
April 26, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on AstraZeneca and increases the price target to $82.
The upgrade in price target by BMO Capital suggests a positive outlook on AstraZeneca's stock, likely due to strong performance or favorable market conditions. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100